推荐产品
等级
pharmaceutical primary standard
API类
spironolactone
制造商/商品名称
EDQM
mp
207-208 °C (lit.)
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]45CCC(=O)O5)[C@H]13
InChI
1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1
InChI key
LXMSZDCAJNLERA-ZHYRCANASA-N
基因信息
human ... NR3C2(4306)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Spironolactone for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化/生理作用
螺内酯是竞争性醛固酮受体拮抗剂。 用作保钾利尿剂。
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
相关产品
产品编号
说明
价格
警示用语：
Danger
危险声明
危险分类
Carc. 2 - Repr. 1B - STOT RE 2
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Spironolactone: an old friend rediscovered.
Domenic A Sica
Journal of clinical hypertension (Greenwich, Conn.), 8(7), 467-469 (2006-07-20)
Well tolerated spironolactone-related hyponatremia.
Joel Handler
Journal of clinical hypertension (Greenwich, Conn.), 10(4), 317-321 (2008-04-11)
Doson Chua et al.
Clinical cardiology, 33(10), 604-608 (2010-10-21)
Spironolactone is used in the treatment of cardiovascular disease, but is contraindicated in renal dysfunction due to the risk of hyperkalemia. It is not known if patients with end-stage renal disease (ESRD) on hemodialysis are at the same risk for
Enrico Vizzardi et al.
The American journal of the medical sciences, 347(4), 271-276 (2013-11-08)
The purpose of this study is to evaluate long-term effects of spironolactone, an affordable and widely used aldosterone receptor blocker, in patients with heart failure (HF) and mild or no symptoms. The study is a single-blind, placebo-controlled, blinded endpoint, randomized
Oscar M P Jolobe
European journal of internal medicine, 24(4), 303-309 (2012-12-19)
The evolution of strategies for the use of spironolactone and its analogue, eplerenone, has, over the years, encompassed favourable modification of the natural history of symptomatic heart failure in subjects with subnormal left ventricular ejection fraction (LVEF), and mitigation of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持